Process for Enhancing the Activity of Amyloid β Peptides by Hensley, Kenneth et al.
University of Kentucky
UKnowledge
Chemistry Faculty Patents Chemistry
11-24-1998
Process for Enhancing the Activity of Amyloid β
Peptides
Kenneth Hensley
University of Kentucky
D. Allan Butterfield
University of Kentucky, david.butterfield@uky.edu
John M. Carney
University of Kentucky
Michael Aksenov
University of Kentucky
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/chemistry_patents
Part of the Chemistry Commons
This Patent is brought to you for free and open access by the Chemistry at UKnowledge. It has been accepted for inclusion in Chemistry Faculty Patents
by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Recommended Citation
Hensley, Kenneth; Butterfield, D. Allan; Carney, John M.; and Aksenov, Michael, "Process for Enhancing the Activity of Amyloid β
Peptides" (1998). Chemistry Faculty Patents. 28.
https://uknowledge.uky.edu/chemistry_patents/28
US005840838A 
Ulllted States Patent [19] [11] Patent Number: 5 840 838 9 9 
Hensley et al. [45] Date of Patent: Nov. 24, 1998 
[54] PROCESS FOR ENHANCING THE ACTIVITY 5,250,660 10/1993 Shuman ................................ .. 530/344 
OF AMYLOID [3 PEPTIDES OTHER PUBLICATIONS 
[75] Inventors? Kenneth Hensley; D- Allan W. Bruce Rowe, et al., “Glutamine Synthetase (Sheep 
Butter?eld; John Carney; Michael Brain)”, 1951, pp 9()()_91()_ 
Aksellov, all of Lexlngton, Ky- Richard E. Miller, et al., “Regulation of glutamine syn 
_ _ _ thetase in cultured 3T3—L1 cells by insulin, hydrocortisone, 
[73] Asslgneei UIHVBYSIPY of Kentucky Research and dibutyryl cyclic AMP”, Jan. 9, 1978, pp. 1418—1422. 
Foundatlom Lexlngton, KY Waite et al., Neuro. Aging vol. 03 (1992) pp. 595—599. 
Stricht et al., Eur. J. Biochem. vol. 233 (Oct. 1995) 293—298. 
[21] Appl. No.: 609,090 Hensley et al. Neuroreport vol. 6 No. 3 (Feb. 15, 1995) 
[22] Filed: Feb. 29, 1996 489_492' 
Primary Examiner—Cecilia J. Tsang 
6 . [51] Int. Cl. ............................ .. C07K 7/00, C07K 14/00 Assistant Examiner_Bennett Celsa 
U-S. Cl. ........................ .. Attorney) Or D/ICDermOtt, & Emery 
530/328; 530/344 
[58] Field Of Search ................................... .. 530/324, 326, [57] ABSTRACT 
530/327’ 328’ 344 Anovel rocess for enhancin activit of an oli 0 e tide or P g y g P P 
[56] References Cited polypeptide comprising the 'steps of: providing an oligopep 
tide or polypeptide, dissolving the oligopeptide or polypep 
U.S. PATENT DOCUMENTS tide in an organic solvent, heating, removing the solvent, and 
_ recovering an oligopeptide or polypeptide With enhanced 
4,337,194 6/1982 DiaZ et a1. ......................... .. 260/112.5 activit is disclosed Also disclosed are novel on 0 e tides 
4,530,784 7/1985 Rosenberg ..... .. 260/112 R d Y1 .d ‘h d b h g 5’. p h 
4,666,829 5/1987 Glenner et a1. .. ..... .. 435/6 3“ Pt? ypep“ es 6“ ance y t 6 Process “Cor mg t 6 
4,966,963 10/1990 PatfOIli ........... .. 530/351 “Wen 10“ 
5,144,006 9/1992 Tam ....................... .. 530/345 
5,213,962 5/1993 Van Nostrand et a1. .............. .. 435/71 11 Claims, 6 Drawing Sheets 
U.S. Patent Nov. 24, 1998 Sheet 1 of6 5,840,838 
5,840,838 U.S. Patent 
7% 
_ _
7 65 432.l0
£5: E255u
+TFE -TFE 
FIG. 2 
U.S. Patent Nov. 24, 1998 Sheet 3 of6 5,840,838 
+TFE-AB 
////////////% % /////////// 
+AB 
FIG. 3 
PBN 
B A 
m +
DI 
Q T////// 
D 
U S Patent Nov. 24, 1998 Sheet 4 0f 6 5,840,838 
U S Patent Nov. 24, 1998 Sheet 5 0f 6 5,840,838 
AD m 
U.S. Patent Nov. 24, 1998 Sheet 6 of6 5,840,838 
5,840,838 
1 
PROCESS FOR ENHANCING THE ACTIVITY 
OF AMYLOID [3 PEPTIDES 
This invention Was made With Government support 
under Grant No. AG-10836 awarded by the National Insti 
tute of Health. The Government may have certain rights in 
this invention. 
FIELD OF THE INVENTION 
This invention relates to a novel process for enhancing 
activity of an oligopeptide or polypeptide comprising the 
steps of: providing an oligopeptide or polypeptide, dissolv 
ing the oligopeptide or polypeptide in an organic solvent, 
heating, removing the solvent, and recovering an oligopep 
tide or polypeptide With enhanced activity. The present 
invention also provides novel oligopeptides and polypep 
tides enhanced by the process according the invention. 
BACKGROUND 
Amyloid [3 peptide is a 39-43 residue peptide Which is a 
proteolytic product of amyloid precursor protein. Amyloid [3 
peptide comprises the 28 amino acids immediately amino 
terminal to the single transmembrane domain of the precur 
sor plus the ?rst 11—15 residues of that domain. The amyloid 
[3 peptide contains both hydrophobic and hydrophilic 
domains. Amyloid plaques, a brain lesion diagnostic of 
AlZheimer’s disease, are composed primarily of amyloid [3 
peptide. Synthetic amyloid [3 peptides are toxic to central 
nervous system neurons in vitro. While the mechanism for 
this neurotoxicity is poorly understood, there have been 
reports that the neurotoxicity results from free radical pro 
duction enhanced by the peptide. 
Various processes for preparing and purifying biological 
materials are knoWn in the art. For example, US. Pat. No. 
4,966,963 to Patroni discloses a method for the preparation 
of a protein in a biologically active or native form, Which 
method includes (1) providing a source of protein in a 
solubiliZed form and an agent capable of rupturing atomic 
forces Within the molecule, and (2) contacting the protein 
With the atomic forces rupturing agent in an amount suf? 
cient to alloW the protein to convert to physiologically active 
form. The patent discloses that protein aggregates Which 
may be recovered are selected from protein precipitates 
including inclusion bodies and cytoplasmic aggregates. 
US. Pat. No. 5,144,006 to Tam relates to a method for the 
oxidative folding of a peptide or protein substrate containing 
reactive sulfhydryl groups to form disul?de rings on bridges 
by reacting the substrate in an aqueous media With DMSO 
or other hydrocarbon sul?tes. Other hydrocarbon sul?tes 
include substituted hydrocarbons in Which hydrogen is 
replaced With a reaction inert substituent such as hydroxy or 
halogen. These include symmetrical and non-symmetrical 
dialkyl sulfoxide containing up to six carbon atoms and 
further compounds in Which the sulphur atom and the carbon 
atoms to Which it is joined form a cyclic alkylene sulfoxide 
containing four or ?ve carbon atoms. 
US. Pat. No. 4,530,784 to Rosenberg relates to a method 
of extracting a biologically active factor that restores contact 
inhibition of groWth to malignant cells in mammals by 
mixing a media conditioned by groWth of a contact inhibited 
cell culture together With a volatile non-denaturing precipi 
tating agent. The precipitate formed by this reaction is 
separated from the mixture and extracted With a biologically 
acceptable ionic buffering agent. 
US. Pat. No. 4,337,194 to DiaZ et al. relates to a process 
for the preparation of somatostatin Wherein a step-Wise 
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peptide coupling reaction is affected in solution in DMF and 
the product of the reaction is isolated by evaporation of the 
DMF or by precipitation by addition of a second solvent 
Which renders the somatostatin insoluble. Then, the obtained 
crude peptide is puri?ed by solid phase Washings With the 
aid of suitable solvents Which dissolve the impurities. 
U.S. Pat. No. 5,250,660 to Shuman relates to a process for 
the puri?cation of peptides comprising chromatographing 
the impure salt of certain tripeptides via reversed phase high 
performance liquid chromatography by employing a gradi 
ent of about 2% to about 40% acetonitrile in an aqueous 
phase containing an inorganic acid corresponding to the salt 
form of the tripeptide at a pH betWeen about 2 and about 3. 
FolloWing the collection of the salt of the tripeptide in the 
eluate, the pH of the eluate is adjusted With Water insoluble 
resin in basic form to betWeen about pH 4 to about pH 6, 
?ltering the resin and isolating the pure salt by removing the 
Water from the ?ltrate. 
U.S. Pat. No. 5,213,962 to Van Nostrand et al. relates to 
the puri?cation, detection and methods of use of protease 
nexin-2 (PN-2) Which is believed to be derived from the 
[3-amyloid precursor protein. The patent discloses a method 
for purifying PN-2 employing a monoclonal antibody pro 
duced by Hybridoma Cell Line mAbP2-1 in an immunoaf 
?nity step. In this method, pooled PN-2 containing fractions 
from a primary dextran sulphate-sepharose af?nity step Were 
directly applied to a mAbP2-1 monoclonal antibody immu 
noaf?nity column. After Washing, apparently homogenous 
PN-2 Was eluted With loW pH buffer. The overall activity 
yield from numerous puri?cations Was betWeen 70—85%. 
U.S. Pat. No. 4,666,829 to Glenner et al. discloses a novel 
polypeptide Which is used as a marker for AlZheimer’s 
disease. The polypeptide can be used to obtain antibodies 
Which Will recogniZe antigenic determinants of the polypep 
tide or homologous polypeptides in tissues or body ?uids 
and Which may be used in a speci?c immunologic diagnostic 
test for AlZheimer’s disease. Moreover, the polypeptide can 
be used to produce a nucleotide probe Which can hybridiZe 
With the gene Which codes for this or a homologous polypep 
tide. Such a probe can also be utiliZed in a speci?c diagnostic 
test for the disease. 
U.S. Pat. No. 5,262,332 to Selkoe relates to a method for 
screening for AlZheimer’s disease, comprising the steps of: 
obtaining a skin tissue biopsy sample from a patient 
suspected of having AlZheimer’s disease; performing 
an extraction suitable for extracting [3-amyloid protein, 
or a [3-amyloid precursor protein fragment comprising 
[3-amyloid protein, from the biopsy sample, and thereby 
obtaining an extract sample; optionally additionally 
solubiliZing the [3-amyloid protein or the [3-amyloid 
precursor protein fragment comprising [3-amyloid pro 
tein present in the extract sample, and thereby obtain 
ing a solution sample; 
contacting the extract sample or the solution sample With 
a quantity of antibodies speci?c to [3-amyloid protein or 
to a precursor protein fragment comprising [3-amyloid 
protein or to a peptide fragment of [3-amyloid protein of 
at least about eight amino acids suf?cient to alloW 
detection of said protein, protein fragment or peptide 
fragment; and, detecting the speci?c binding reaction in 
the extract or solution sample betWeen the antibodies 
and the [3-amyloid protein or the [3-amyloid precursor 
protein fragment comprising [3-amyloid protein 
Wherein the presence of said binding reaction is indica 
tive of AlZheimer’s disease. 
Many oligopeptides and polypeptides are necessary 
research tools for the study of pathWays underlying various 
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diseases. For example, synthetic amyloid B peptides are a 
necessary research tool for the study of the neurotoxicity 
that results from free radical production enhanced by the 
amyloid [3 peptide. Unfortunately, some oligopeptides and 
polypeptides such as synthetic amyloid [3 peptides demon 
strate signi?cant lot-to-lot variations in toxicity Which is not 
attributed to contaminants or peptide impurities and Which 
decreases their commercial value. More speci?cally, peptide 
reactivity greatly varies betWeen synthetic lots due to struc 
tural factors. This variation is a major impediment because 
research cannot be accurately reproduced. None of the 
above-described processes and methods adequately address 
this problem. Thus, a long-felt need in the art exists for a 
process for treating oligopeptides and polypeptides such as 
synthetic amyloid B peptides, and other synthetic peptides, 
to create more uniformity in research applications. The 
present invention addresses this need. 
SUMMARY OF THE INVENTION 
It is accordingly one object of the present invention to 
provide a novel process for enhancing activity of an oli 
gopeptide or polypeptide comprising the steps of: providing 
an oligopeptide or polypeptide, dissolving the oligopeptide 
or polypeptide in an organic solvent, heating, removing the 
solvent, and recovering an oligopeptide or polypeptide With 
enhanced activity. 
Another object of the invention is to provide a novel 
process for enhancing activity of an oligopeptide or 
polypeptide Wherein there is negligible sample loss. 
A further object of the present invention is to provide 
novel oligopeptides and polypeptides enhanced by the pro 
cess according the invention. 
The above and other objects of the invention Will become 
readily apparent to those of skill in the relevant art from the 
folloWing detailed description, Wherein only the preferred 
embodiments of the invention are shoWn and described, 
simply by Way of illustration of the best mode of carrying 
out the invention. As is readily recogniZed, the invention is 
capable of modi?cations Within the skill of the relevant art 
Without departing from the spirit and scope of the invention. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shoWs the PBN spin adducts formed by 
co-incubation of A[3(1-40) (SEQ ID NO:8) before and after 
the TFE-restructuring process; 
FIG. 2 shoWs that the yield of spin adduct Was at least 
tripled after TFE treatment upon a double integration of the 
spectra; 
FIG. 3 shoWs the results of GS toxicity assays performed 
in parallel With, and using aliquots of the sample peptide 
preparations; 
FIGS. 4A—4D shoW electron micrographs of A[3(1-40) 
(SEQ ID NO:8) before and after TFE-SARP and incubated 
in PBS for 24 hours in the presence and absence of 50 mM 
PBN; and 
FIGS. 5A—5D shoW the EPR spectra of PBN spin adducts 
formed from A[3(25-35) before and after TFE- or DMSO 
treatment. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The present invention provide a novel process for enhanc 
ing activity of an oligopeptide or polypeptide comprising the 
steps of: providing an oligopeptide or polypeptide, dissolv 
ing the oligopeptide or polypeptide in an organic solvent, 
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heating, removing the solvent, and recovering an oligopep 
tide or polypeptide With enhanced activity. The invention is 
based, in part, on the inventors’ surprising and unexpected 
discovery that the process increases the chemical reactivity, 
biological functioning and aggregational characteristics of 
oligopeptides and polypeptides. 
The present invention is particularly applicable to bio 
logically active structure dependent oligopeptides and 
polypeptides. These oligopeptides and polypeptides may be 
puri?ed or unpuri?ed, and natural or synthetic. These bio 
logically active polypeptides and peptides include groWth 
hormones, interferons, immunogens, lymphokines, amyloid 
beta peptides, substance P peptide, catalytic antibodies, 
enZymes, and fragments thereof. Examples of synthetic 
oligopeptides and polypeptides corresponding to the amy 
loid beta peptide include A[3(1-15) (SEQ ID NO:1), A[3(1 
28) (SEQ ID NO:2), A[3(1-30) (SEQ ID NO:3), A[3(1-33) 
(SEQ ID NO:4),A[3(25-35) (SEQ ID NO:5),A[3(1-36) (SEQ 
ID NO:6), A[3(1-39) (SEQ ID NO:7), A[3(1-40) (SEQ ID 
NO:8), A[3(1-42) (SEQ ID NO:9), A[3(1-47) (SEQ ID 
NO:10), and A[3(1-52) (SEQ ID NO:11). 
The oligopeptide or polypeptide may be dissolved in any 
suitable structure forming organic solvent, that is, solvents 
Which modulate protein secondary and higher order struc 
ture. Suitable structure forming solvents include 
tri?uoroethanol, dimethyl sulfoxide, 
hexa?uorocyclohexane, morpholino-propanesulfonic acid, 
dimethylformamide, and acetonitrile. In a preferred 
embodiment, the oligopeptide or polypeptide is pre-treated 
With the solvent. 
Before pre-treatment of the oligopeptide or polypeptide 
With the solvent and/or before dissolving the oligopeptide or 
polypeptide in the solvent, the solvent may be deoxygenated 
by any suitable means, for example, by thoroughly degas 
sing by N2 sparge. 
The oligopeptide or polypeptide is dissolved in the sol 
vent to an appropriate concentration ranging from about 
0.01 to 10 mg/ml, preferably from about 0.1 to 5 mg/ml, and 
more preferably from about 0.15 to 1.0 mg/ml. 
Then, the dissolved oligopeptide or polypeptide is 
incubated, for example, in glass vials, for a period of time 
ranging from about 30 minutes to about 4 hours, preferably 
from about 45 minutes to 3 hours, more preferably from 
about 1 hour to about 2 hours. 
During incubation the samples are gently heated to any 
suitable temperature. Preferably temperatures ranging from 
about 20° to about 65° C., more preferably from about 40° 
to about 45° C. are used. 
The sample may be equilibrated to room temperature 
before removing the solvent or the solvent may be removed 
immediately. The solvent may be removed by any appro 
priate method, so long as the method is suitable for the 
solvent and oligopeptide or polypeptide. Preferred methods 
for removing the solvent include evaporative deposition, for 
example, under a stream of N2 gas, and lyophiliZation. The 
duration of the solvent removal step is (rapid) about 5 
minutes to about 10 minutes. 
The present invention also provides novel oligopeptides 
and polypeptides enhanced by the process according the 
invention. 
The folloWing examples are merely illustrative of the 
present invention and they should not be considered as 
limiting the scope of the invention in any Way, as these 
examples and other equivalents Will become more apparent 
to those skilled in the art in light of the present disclosure. 
EXAMPLE 1 
Solvation Activation Process 
Tri?uoroethanol (TFE) (Aldrich Chemical, MilWaukee, 
Wis.) Was initially thoroughly degassed by N2 sparge. 
5,840,838 
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Samples of synthetic amyloid beta peptide, A[3(1-40) (SEQ 
ID NO:8) [Bachem lot ZM094], Were divided into TFE 
treated and control samples. TFE-treated samples Were 
dissolved in deoxygenated TFE to a concentration of 0.15 
mg/ml and incubated in glass vials for 2 hours at 40°—45° C. 
The TFE/AB solution Was initially cloudy but became clear 
after about 1 hour at 40° C. The TFE/AB solutions Were 
equilibrated to room temperature folloWed by removal of the 
TFE by rapid evaporation under a stream of N2 gas. 
EXAMPLE 2 
Peptide Toxicity Assessed By Glutamine Synthetase 
Inactivation 
Glutamine synthetase (GS) Was assayed in brain cortical 
homogenate prepared from male mongolian gerbils 
(Tumblebrook Farms, W. Brook?eld, Mass.). Amyloid beta 
peptide Was tested for its ability to inactivate GS by ?rst 
preincubating the peptide for 24 hours in phosphate buffer (1 
mg/ml concentration, 5 mM K2HPO4/KH2PO4+5 mM NaCl 
pH 7.0) then co-incubating the peptide solution With brain 
cytosolic extract prepared from gerbil cortical homogenates 
(brain protein concentration in incubate=0.2 mg/ml, peptide 
concentration 1 mg/ml). After 3 hours incubation at 37° C. 
in phosphate buffer, aliquots of GS/peptide co-incubate Were 
removed and assayed for GS activity by the calorimetric 
method of RoWe et al., Glutamine Synthetase, Methods 
EnZymol. 17 NeW York: Academic Press, 1970: 900—910; as 
modi?ed by Miller et al., Proc. Natl. Acad. Sci. USA 75, 
1418—1422 (1978) and corrected for nonspeci?c glutami 
nase activity by comparison in the presence and absence of 
ADP and arsenate. 
Toxic AB inactivates the oxidation-sensitive enZyme 
glutamine synthetase (GS) in vitro, and this measure of 
toxicity is used to index relative reactivity of AB samples. 
FIG. 3 illustrates the results of GS toxicity assays performed 
in parallel With, and using aliquots of the sample peptide 
preparations. The GS activity in this experiment is expressed 
relative to the initial GS activity of brain extract before 
incubation at 37° C., during Which some GS activity is 
inevitably lost (even in the absence of added peptide) due to 
spontaneous oxidation of the sensitive enZyme. The activity 
of the enZyme decreases by approximately 30% after 3 hours 
incubation in the absence of AB. In the presence of unmodi 
?ed A[3(1-40) (SEQ ID NO:8) (Bachem lot ZM094), GS 
activity decreases approximately 45% relative to its initial 
activity. Thus, the peptide appears to have some toxic 
potential, but signi?cantly less than has been previously 
reported With regard to the A[3(1-40) (SEQ ID NO:8) or the 
toxic A[3(25-35) (SEQ ID NO:5) sequences. TFE-treated 
A[3(1-40) (SEQ ID NO:8) engenders a much greater loss in 
GS activity after 3 hours coincubation. These samples lost 
over 90% of initial GS activity. This represents a 3-fold 
increase in toxicity of the native, unmodi?ed AB correlating 
With the EPR spin trapping results described herein. 
In all cases, inclusion of 50 mM PBN in the GS incubate 
inhibited spontaneous GS oxidation and also A[3-mediated 
loss in GS activity (FIG. 3). BetWeen the PBN/AB 
containing samples, GS activity shoWed a 3-fold greater 
decrease in the presence of TFE-pretreated AB than in the 
presence of native, unmodi?ed AB , again in close correla 
tion to EPR results obtained from these treatments. 
EXAMPLE 3 
Peptide Free Radical Generating Capacity 
Amyloid beta free radical generation Was assessed by 
electron paramagnetic resonance (EPR) spin trapping. Amy 
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loid beta peptide (1 mg/ml) Was incubated With phenyl-tert 
butylnitrone [50 mM PBN (Centaur Pharmaceuticals, 
Sunnyvale, Calif.) in 5 mM K2HPO4/KH2PO4+5 mM NaCl 
pH 7.0] at 37° C. for 1—24 hours, then analyZed by EPR 
spectrometry using a Bruker 300 EPR spectrometer 
(incident poWer=19 mW, incident frequency=9.76 GHZ, 
modulation amplitude=0.9 G, time constant=1.28 mS, con 
versiton time=10.28 mS). 
Reactive amyloid beta produces stable free radical 
adducts of PBN Which are detectable and quanti?able by 
EPR. The type and quantity of PBN adduct produced upon 
reaction with A6 correlates With the degree of GS toxicity or 
cytotoxicity inherent in the AB sample. FIG. 1 shoWs the 
PEN spin adducts formed by conincubation of A[3(1-40) 
(SEQ ID NO:8) [Bachem lot ZM094] before and after the 
TFE-restructuring process. Although, the spectra are quan 
titatively similar, the TFE-treated sample produced a sig 
ni?cantly greater yield of spin-adduct and double integration 
of the spectra shoWed that the yield of spin adduct Was at 
least tripled after TFE treatment (FIG. 2). 
EXAMPLE 4 
Peptide Aggregation Assessment by Electron 
Microscopy 
Amyloid beta peptide Was preincubated at 1 mg/ml for 24 
hours at 37° C. in phosphate buffer :50 mM PBN. 20 uL 
aliquots of the peptide incubate Were evaporated to dryness 
on silicon grids and counterstained With uranyl acetate. 
Electron microscopy Was performed on a Hitachi 7000 
transmission electron microscope operating at 75 KV. 
FIG. 4 shoWs electron micrographs of A[3(1-40) (SEQ ID 
N018) before and after TFE-SARP and incubated in PBS for 
24 hours in the presence and absence of 50 mM PBN. These 
also represent aliquots of samples used in the EPR and 
enZyme activity investigations. The native, unmodi?ed AB 
formed visible ?brils upon incubation in the buffer. Native, 
unmodi?ed AB coincubated With PBN demonstrated both 
?brils and an amorphous component Which stains more 
lightly and spans the inter?brillar regions. TFE-AB treat 
ments differed dramatically in morphology from the native, 
unmodi?ed peptide. TFE-treated AB formed very feW ?brils, 
and along the ?bril tracks Were numerous circular or oblong 
deposits and regions of dark amorphous staining. In the 
presence of PBN, the ?bril density appeared someWhat 
greater than in PBN absence; the circular components Were 
smaller and sparcer; and lightly stained intra?brillar material 
Was seen in the PBN-coincubated, native AB samples. 
EXAMPLE 5 
Activation of A[3(25-35) (SEQ ID NO:5) 
The reactivity of loW-activity A[3(25-35) (SEQ ID NO:5) 
[Bachem lot WL650] Was modi?ed by TFE- and DMSO 
treatment of the original peptide lyophilate. FIG. 5 shoWs 
the EPR spectra of PBN spin adducts formed from A[3(25 
25) (SEQ ID NO:5) before and after TFE- or DMSO 
treatment. The TFE-treated peptide shoWed a qualitatively 
different reactivity than the native peptide, producing a 
3-line EPR spectrum rather than a 4-line spectrum. Previous 
data shoWed a strong correlation betWeen peptide toxicity 
and PBN spin adduct spectra, With 3-line generating pep 
tides more toxic than 4-line generating variants. The DMSO 
treated peptide demonstrated both the 4-line component and 
a nascent but Weak 3-line component. Control experiments 
using H2O in place of the organic solvent had no effect on 
the nature of the PBN spin adduct. 
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EXAMPLE 6 
Morphology of Aggregate Structures 
Toxic AB has a very facile ?bril-forming capacity, 
Whereas loW-activity samples of AB form small amorphous 
or unstructured aggregates. The type of aggregate or poly 
mer formed in the AB may re?ect the initial aggregate 
condition of reactive polymolecular structures present in the 
peptide lyophilate prior to solubiliZation, and hence should 
be effected by protocols designed to modulate peptide 
structure and toxicity. FIG. 5 shoWs electron micrographic 
evidence that TFE treatment dramatically modi?ed peptide 
?brillogenic potential. The slightly toxic, native peptide 
formed a moderately dense netWork of ?laments after 24 
hours incubation in phosphate buffer (FIG. 5A). TFE-treated 
peptide formed only sparse ?brils, along Which are located 
circular or spherical structures and opaquely-stained regions 
(FIG. 5B). This Was the case in both PBN-free and PBN 
coincubated, TFE-treated A[3(1-40) (SEQ ID NO:8). In the 
PBN-treated samples, ?bril density Was slightly greater, and 
the spherical inclusions Were smaller and feWer. In the PBN 
coincubated samples (both native and TFE-treated peptide), 
there Were lightly stained deposits spanning the inter?brillar 
regions (FIG. 5 CD). In control experiments Where the PBN 
Was added after the 24 hour peptide preincubation period 
(i.e., after ?brillogenesis), these highly stained deposits Were 
not visible. Therefore, the lightly-stained PBN-derived 
structure represents a feature of PBN/AB interaction rather 
than simply a result of PBN precipitation. 
EPR spectroscopy, enZyme assay, and electron micros 
copy have demonstrated a dramatic modi?cation in reactiv 
ity of synthetic A[3(1-40) (SEQ ID NO:8) upon treatment 
With the process of the present invention. The 3-fold 
increase in EPR signal intensity and GS inactivation upon 
TFE treatment, along With the observation that GS activity 
is protected by PBN inclusion, shoWs that the oxidative 
potential of the AB peptide is markedly increased by TFE 
mediated unfolding and subsequent refolding of the peptide. 
The electron microscopic data clearly indicate a difference 
in aggregation behavior betWeen native and TFE-treated AB. 
While not Wishing to be bound by any particular theory, 
it is possible that lot-to-lot variations in potency among 
synthetic AB peptides stem from alternate positioning of 
reactive radicaliZation sites Within polymolecular aggregates 
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of the peptide lyophilate. By separating and unfolding small 
polymolecular aggregates in the lyophilate and thereby 
freeing previously concealed reactive peptide radicaliZation 
sites, the present process signi?cantly enhances the reactiv 
ity of synthetic peptides, including synthetic AB peptides. 
DETAILED DESCRIPTION OF THE DRAWINGS 
FIG. 1: PBN spin adduct EPR spectra obtained from 
synthetic A[3(1-40) (SEQ ID NO:8) before (upper) and after 
(loWer) TFE-treatment as described in the text; 
FIG. 2: Double integrated intensity (arbitrary units) of 
EPR signals corresponding to TFE-treated or native A[3(1 
40) (SEQ ID NO.8) samples; 
FIG. 3: GS inactivation by native and TFE-treated A[3(1 
40) (SEQ ID NO:8). Solid bars indicate samples of A[3(1-40) 
(SEQ ID NO:8) incubated at 1 mg/ml for 24 hours at 37° C. 
in PBS pH 7.0; holloW bars indicate samples that also 
contained 50 mM PBN. After the 24 hour incubation period, 
the peptide samples Were coincubated With brain extract (1 
mg/ml peptide, 0.2 mg/ml brain extract) for 3 hours prior to 
GS assay. Data are represented as % loss of GS activity 
relative to GS samples that Were not subjected to 3 hours of 
37° C. incubation; 
FIG. 4: Electron micrographs ofA[3(1-40) (SEQ ID NO:8) 
after 24 hours incubation in phosphate. A: Native, untreated 
peptide. B: TFE-treated peptide. C: Native peptide coincu 
bated With 50 mM PBN. D: TFE-treated peptide coincubated 
With 50 mM PBN; and 
FIG. 5: PBN spin adduct EPR spectra obtained from 
synthetic A[3(25-35) (SEQ ID NO:5) (lot WL650) treated by 
various solvation procedures prior to coincubation of pep 
tide lyophilate With PBN. A: native, unmodi?ed peptide. B: 
Peptide dissolved in H20 and relyophiliZed prior to spin 
trapping. C: Peptide dissolved in DMSO and relyophiliZed 
prior to spin trapping. ArroWs indicate nascent 3-line com 
ponent. D: Peptide dissolved in TFE and N2 evaporated prior 
to spin trapping. 
The purpose of the above description and examples is to 
illustrate some embodiments of the present invention With 
out implying any limitation. It Will be apparent to those of 
skill in the art that various modi?cations and variations may 
be made to the present invention Without departing from the 
spirit or scope of the invention. 
SEQUENCE LISTING 
( 1 ) GENERAL INFORMATION: 
( i i i )NUMBER OF SEQUENCES: 11 
( 2 ) INFORMATION FOR SEQ ID NO:1: 
( i )SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 15 amino acids 
( B )TYPE: amino acid 
( c ) STRANDEDNESS: single 
( D )TOPOLOGY: linear 
( i i )MOLECULE TYPE: peptide 
( X i )SEQUENCE DESCRIPTION: SEQ ID N0:1: 
Asp Ala Glu Phe Arg 
1 5 
His Asp Se Glu Val His His Gln 
15 
Gly Tyr 
10 
5,840,838 
-c0ntinned 
( 2 ) INFORMATION FOR SEQ ID NO:2: 
( i )SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 28 amino acids 
( B )TYPE: amino acid 
( c )STRANDEDNESS: single 
( D )TOPOLOGY: iiiieai 
( i i ) MOLECULE TYPE: peptide 
( X i ) SEQUENCE DESCRIPTION: SEQ ID NO:2: 
Asp Ala Gln Phe Arg His Asp Ser Gly Tyr Gln Val His His Gln Lys 
1 5 1O 15 
Len Val Phe Phe Ala Gln Asp Val Gly Ser Asn Lys 
2 O 2 5 
( 2 ) INFORMATION FOR SEQ ID NO:3: 
( i )SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 30 amino acids 
( B )TYPE: amino acid 
( C ) STRANDEDNESS: single 
( D )TOPOLOGY: linear 
( i i )MOLECULE TYPE: peptide 
( X i ) SEQUENCE DESCRIPTION: SEQ ID NO:3: 
Asp Ala Gln Phe Arg His Asp Ser Gly Tyr Gln Val His His Gln Lys 
1 5 1O 15 
Len Val Phe Phe Ala Gln Asp Val Gly Ser Asn Lys Gly Ala 
2 O 2 5 3 O 
( 2 ) INFORMATION FOR SEQ ID NO:4: 
( i )SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 33 amino acids 
( B )TYPE: amino acid 
( C ) STRANDEDNESS: single 
( D )TOPOLOGY: linear 
( i i )MOLECULE TYPE: peptide 
( X i ) SEQUENCE DESCRIPTION: SEQ ID NO:4: 
Asp Ala Gln Phe Arg His Asp Ser Gly Tyr Gln Val His His Gln Lys 
1 5 1O 15 
Len Val Phe Phe Ala Gln Asp Val Gly Ser Asn Lys Gly Ala Ile Ile 
2O 25 3O 
Gly 
( 2 ) INFORMATION FOR SEQ ID NO:5: 
( i )SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 11 amino acids 
( B )TYPE: amino acid 
( C ) STRANDEDNESS: single 
( D )TOPOLOGY: linear 
( i i )MOLECULE TYPE: peptide 
( X i ) SEQUENCE DESCRIPTION: SEQ ID NO:5: 
Gly Ser Asn Lys Gly Ala Ile Ile Gly Len Met 
1 5 1 O 
( 2 ) INFORMATION FOR SEQ ID NO:6: 
( i )SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 36 amino acids 
11 
5,840,838 
12 
-continued 
( B )TYPE: amino acid 
( C ) STRANDEDNESS: single 
( D )TOPOLOGY: linear 
( i i )MOLECULE TYPE: peptide 
( X i ) SEQUENCE DESCRIPTION: SEQ ID NO:6: 
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys 
1 5 1O 15 
Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile 
2O 25 3O 
Gly Leu Met Val 
35 
( 2 ) INFORMATION FOR SEQ ID NO:7: 
( i )SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 39 amino acids 
( B )TYPE: amino acid 
( C ) STRANDEDNESS: single 
( D )TOPOLOGY: linear 
( i i )MOLECULE TYPE: peptide 
( X i ) SEQUENCE DESCRIPTION: SEQ ID NO:7: 
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys 
1 5 1O 15 
Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile 
2O 25 3O 
Gly Leu Met ValGly Gly Val 
35 
( 2 ) INFORMATION FOR SEQ ID NO:8: 
( i )SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 40 amino acids 
( B )TYPE: amino acid 
( C ) STRANDEDNESS: single 
( D )TOPOLOGY: linear 
( i i )MOLECULE TYPE: peptide 
( X i ) SEQUENCE DESCRIPTION: SEQ ID NO:8: 
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys 
1 5 1O 15 
Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile 
2O 25 3O 
Gly Leu Met ValGly Gly ValVal 
35 4O 
( 2 ) INFORMATION FOR SEQ ID NO:9: 
( i )SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 42 amino acids 
( B )TYPE: amino acid 
( C ) STRANDEDNESS: single 
( D )TOPOLOGY: linear 
11 :et1e " MOLECULETYPE pp'd 
( X i ) SEQUENCE DESCRIPTION: SEQ ID NO:9: 
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys 
1 5 1O 15 
Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile 
2O 25 3O 
5,840,838 
-continued 
Gly Len Met ValGly Gly ValVal Ile Ala 
35 40 
( 2 ) INFORMATION FOR SEQ ID NO:10: 
( i )SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 47 amino acids 
( B )TYPE: amino acid 
( C ) STRANDEDNESS: single 
( D )TOPOLOGY: linear 
( i i )MOLECULE TYPE: peptide 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:10: 
Asp Ala Gln Phe Arg His Asp Ser Gly Tyr Gln Val His His Gln Lys 
1 5 10 15 
Len Val Phe Phe Ala Gln Asp Val Gly Ser Asn Lys Gly Ala Ile Ile 
20 25 30 
Gly Len Met ValGly Gly ValVal Ile Ala Thr Val Ile Val Ile 
35 40 45 
( 2 ) INFORMATION FOR SEQ ID NO:11: 
( i )SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 52 amino acids 
( B )TYPE: amino acid 
( C ) STRANDEDNESS: single 
( D )TOPOLOGY: linear 
( i i )MOLECULE TYPE: peptide 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:11: 
Asp Ala Gln Phe Arg His Asp Ser Gly Tyr Gln Val His His Gln Lys 
1 5 10 15 
Len Val Phe Phe Ala Gln Asp Val Gly Ser Asn Lys Gly Ala Ile Ile 
20 25 30 
Gly Len Met ValGly Gly ValVal Ile Ala Thr Val Ile Val Ile Thr 
35 40 45 
Len Val Met Len 
50 
We claim: 4. The process of claim 1, Wherein the peptide recovered 
1. Aprocess for treating a synthetic amyloid beta peptide, 
Which process comprising the steps of: 
a) providing a synthetic amyloid beta peptide; 
b) dissolving the synthetic amyloid beta peptide in a 
deoXygenated solvent selected from the group consist 
ing of tri?uoroethanol, dimethyl sulfoXide, 
heXa?uorocycloheXane, morpholino-propanesulfonic 
acid, dimethylformamide, and acetonitrile to a concen 
tration ranging from about 0.01 to about 10 mg/ml; 
c) incubating the dissolved synthetic amyloid beta peptide 
for about 30 minutes to about 4 hours at a temperature 
betWeen about 20° C. to about 65° C.; 
d) removing the solvent by evaporative deposition in 
about 5 to about 10 minutes; and 
e) recovering the synthetic amyloid beta peptide obtained 
in step d. 
2. The process of claim 1, Wherein the peptide recovered 
in step e) produces a three-line or four-line EPR(electron 
paramagnetic resonance) spectrum upon reaction With PBN 
(phenyl-tert-butylnitrone) With an increased integrated 
intensity relative to the provided peptide. 
3. The process of claim 1, Wherein the peptide recovered 
in step e) leads to greater loss of GS(glutamine synthetase) 
activity than the provided peptide. 
in step e) shoWs sparse ?brils along Which are located 
circular or spherical structures and opaquely stained regions 
in an electron micrograph. 
5. The process of claim 1, Wherein the synthetic amyloid 
beta peptide is selected from group consisting of A[3(1-15), 
A[3(1-28), A[3(1-30), A[3(1-33), A[3(25-35), A[3(1-36), A[3(1 
39), A[3(1-40), A[3(1-42), A[3(1-47), and A[3(1-52). 
6. The process of claim 1, Wherein the deoXygenated 
solvent is deoXygenated by N2 sparge. 
7. The process of claim 1, Wherein the synthetic amyloid 
beta is dissolved in the deoXygenated solvent to a concen 
tration of about 0.1 to about 5 mg/ml. 
8. The process of claim 7, Wherein the synthetic amyloid 
beta peptide is dissolved in the deoXygenated solvent to a 
concentration of about 0.15 to about 1.0 mg/ml. 
9. The process of claim 1, Wherein the incubating step is 
carried out at a temperature betWeen about 40° C. to about 
45° C. 
10. A process according to claim 1, Wherein the incubat 
ing step is carried out for about 45 minutes to about 3 hours. 
11. A process according to claim 10, Wherein the incu 
5 bating step is carried out for about 1 hour to about 2 hours. 
a O 
m 
* * * * * 
